Coherus Biosciences traded at $7.50 this Friday June 24th, increasing $0.11 or 1.49 percent since the previous trading session. Looking back, over the last four weeks, Coherus Biosciences gained 1.21 percent. Over the last 12 months, its price fell by 51.33 percent. Looking ahead, we forecast Coherus Biosciences to be priced at 7.30 by the end of this quarter and at 6.72 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
7.50
Daily Change
1.49%
Yearly
-51.33%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
LG Chem 543,000.00 0 0% -36.12%
Fujifilm 7,166.00 116.00 1.65% -11.95%
AbbVie 152.34 2.89 1.93% 34.84%
Acadia Pharmaceuticals 14.98 0.26 1.77% -42.76%
Aerie Pharmaceuticals 7.56 0.24 3.28% -59.74%
Akebia Therapeutics 0.37 -0.03 -7.12% -91.30%
ALKERMES 29.71 0.15 0.51% 23.12%
Alnylam Pharmaceuticals 147.50 1.20 0.82% -15.90%
Amgen 245.37 2.28 0.94% 1.11%
Amarin 1.92 -0.07 -3.52% -58.44%
Baxter International 66.78 1.70 2.61% -18.75%
Biogen 211.93 0.55 0.26% -39.09%
Bluebird Bio 4.40 0.12 2.80% -85.77%
BioMarin Pharmaceutical 86.85 2.30 2.72% 2.43%
Bristol-Myers Squibb 78.96 1.27 1.63% 18.31%
Coherus Biosciences 7.50 0.11 1.49% -51.33%
Endo International 0.37 -0.02 -5.72% -92.53%
Gilead Sciences 63.08 0.50 0.80% -7.07%
Horizon Pharma 85.13 2.22 2.68% -11.25%
Ironwood Pharmaceuticals 11.30 0.25 2.26% -13.74%
Jazz Pharmaceuticals 153.49 2.72 1.80% -15.24%
Eli Lilly 325.62 12.90 4.13% 41.44%
Merck & Co 93.13 1.13 1.23% 20.63%
Myriad Genetics 18.95 0.05 0.26% -41.89%
Pacira 57.43 1.15 2.04% -9.59%
Pfizer 51.59 1.50 2.99% 32.35%
Perrigo 41.21 0.90 2.23% -12.09%
PTC Therapeutics 40.22 0.11 0.27% -8.30%
Regeneron Pharmaceuticals 612.49 5.10 0.84% 11.25%
Revance Therapeutics 15.28 0.15 0.99% -50.42%
Sarepta Therapeutics 75.22 3.40 4.73% -6.44%
Teva Pharmaceutical Industries Ltd 2,689.00 12.00 0.45% -20.84%
Vertex Pharmaceuticals 292.55 9.05 3.19% 50.54%
Xencor 27.12 0.54 2.03% -25.29%
Zoetis 174.61 5.44 3.22% -6.74%

Indexes Price Day Year
USND 11608 375.43 3.34% -19.17%
US400 2334 80.04 3.55% -14.38%

Coherus Biosciences
Coherus BioSciences, Inc. is a commercial stage biotherapeutics company. The Company is focused on the biosimilar and immuno-oncology market primarily in the United States. The Company’s pipeline includes the four categories product candidates, Oncology pipeline, Immunology pipeline, Ophthalmology pipeline and Small Molecule pipeline. Oncology pipeline includes Toripalimab, an anti-PD-1 antibody; UDENYCA (pegfilgrastim-cbqv); CHS-305, a bevacizumab (Avastin) biosimilar. Immunology pipeline includes CHS-1420, an anti-TNF product candidate, as an adalimumab (Humira) biosimilar. Ophthalmology pipeline includes CHS-201, a ranibizumab (Lucentis) biosimilar. CHS-201, a ranibizumab (Lucentis) biosimilar. Small Molecule pipeline includes CHS-131, an oral, small-molecule drug candidate. CHS-131 is a once-daily oral drug candidate for non-alcoholic steatohepatitis (NASH) and other metabolic conditions.